Surman, Peter

Peter Surman is a biologist and science writer with a focus on infrared photonics and bio-inspired nanoarchitectures. He has published extensively on the topic of biological systems and their applications in technology, particularly in the field of infrared imaging. His work has been supported by DARPA and General Electric's fundamental research funds. In addition to his scientific contributions, Surman is known for his engaging writing style and ability to make complex scientific concepts accessible to a broad audience.

Biography:  https://www.nature.com/articles/nphoton.2011.355

4%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a poor reputation for journalistic standards and is not considered a reliable news source.

Bias

10%

Examples:

  • The author appears to have a strong understanding of and respect for the scientific method and process.
  • There are no instances of logical fallacies or misleading statements in the provided text.

Conflicts of Interest

0%

Examples:

  • There are no instances of conflicts of interest or financial ties that could influence the author's findings or conclusions.

Contradictions

0%

Examples:

  • No major contradictions were found in the provided text.

Deceptions

0%

Examples:

  • No instances of deceptive practices were found in the provided text.

Recent Articles

Ketamine Tablets: A Promising Alternative for Treating Severe Depression - New Studies and Findings

Ketamine Tablets: A Promising Alternative for Treating Severe Depression - New Studies and Findings

Broke On: Monday, 24 June 2024 New studies suggest that oral ketamine tablets, a promising alternative to traditional forms of administration for severe depression treatment, have shown significant reductions in depression symptoms and lower relapse rates compared to placebo in treatment-resistant major depression patients. The convenience and safety of this at-home option warrant further investigation.